Stacy Graham, MD
Interventional Cardiology · Columbia, SCNPI 1912093501
Payments from drug & device makers
Across 392 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Cardiovascular Systems Inc.$1K
- Novartis$1K
- Amgen$898
- Pfizer$660
- Boston Scientific$405
- plus $3K from 28 others
What the payments were for
- Travel & lodging$1,22115%
- Food & beverage$7,04685%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 36 | $1,448 |
| Cardiovascular Systems Inc. | 11 | $1,427 |
| Novartis | 78 | $1,283 |
| Amgen | 55 | $898 |
| Pfizer | 34 | $660 |
| Boston Scientific | 14 | $405 |
| Merck | 27 | $395 |
| AstraZeneca | 20 | $385 |
| Johnson & Johnson | 25 | $354 |
| Boehringer Ingelheim | 22 | $345 |
| Medtronic(2 entities) | 3 | $308 |
| Novo Nordisk | 10 | $241 |
| Atricure, Inc. | 7 | $165 |
| Abbott | 8 | $156 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $141 |
| Alnylam Pharmaceuticals Inc. | 6 | $107 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $68 |
| Esperion Therapeutics, Inc. | 4 | $63 |
| Cvrx, Inc. | 3 | $61 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $57 |
| Actelion Pharmaceuticals US, Inc. | 2 | $49 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Scpharmaceuticals Inc. | 3 | $45 |
| Corcept Therapeutics | 2 | $39 |
| Philips North America LLC | 1 | $26 |
| Amryt Pharma Holdings Ltd | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $19 |
| Altathera Pharmaceuticals LLC | 1 | $17 |
| Terumo Medical Corporation | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Bayer | 1 | $14 |
| Cashflow Solutions, LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Coronary Orbital Atherectomy System$1,332
- Micra$137
- LINQ II$108
- Watchman$102
How this compares
$9,316 in reported general payments places this provider in the 40th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 522 | $501,604 |
| XareltoRivaroxaban | 137 | $150,120 |
| EntrestoSacubitril/Valsartan | 101 | $137,620 |
| CamzyosMavacamten | 13 | $109,588 |
| JardianceEmpagliflozin | 80 | $101,044 |
| FarxigaDapagliflozin Propanediol | 74 | $64,200 |
| Repatha SureclickEvolocumab | 84 | $63,721 |
| Valsartan | 329 | $9,372 |
| Metoprolol Succinate | 450 | $8,426 |
| Rosuvastatin Calcium | 311 | $6,222 |
| Atorvastatin Calcium | 427 | $5,164 |
| Ezetimibe | 106 | $3,511 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 84 | $2,844 |
| Amlodipine Besylate | 441 | $2,800 |
| Nifedipine ErNifedipine | 57 | $2,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $660 | $501,604522 claims |
| Johnson & JohnsonXarelto | $354 | $150,120137 claims |
| NovartisEntresto | $1,283 | $137,620101 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $1,448 | $109,58813 claims |
| Boehringer IngelheimJardiance | $345 | $101,04480 claims |
| AstraZenecaFarxiga | $385 | $64,20074 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Columbia
- Kurt BarringhausColumbia$536K
- Vince VismaraColumbia$142K
- Loren MorganColumbia$127K
- Patrick HallColumbia$126K
- Michael CryerColumbia$92K
- Michael FosterColumbia$74K
- James PhillipsColumbia$61K
- George YankeyColumbia$41K
- Gopi ShahColumbia$29K
- Matthew CantrellColumbia$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.